Special Issue

Pioneering the Microbiome— Infections, Inflammation, Inflammatory Bowel Disease and the Role of Antibiotic Therapy

Message from the Guest Editors

This Special Issue will explore the dynamic interplay between the human microbiome, infectious agents, mucosal inflammation, and the therapeutic use of antibiotics in gastrointestinal disease, particularly in inflammatory bowel disease. Emerging evidence supports the concept that specific pathobionts are involved in chronic intestinal inflammation. This Special Issue welcomes original research, reviews, and clinical case studies investigating the following topics:Antibiotic-responsive microbial subtypes in Crohn's disease and ulcerative colitis; Mechanisms of biofilm disruption and inflammation resolution; Detection of elusive pathogens and how to eradicate infections and restore normobiosis; Targeting intracellular bacteria by various strategies; Antibiotics and microbial metabolites influencing immune regulation. By bridging infectious disease paradigms with modern microbiome science, this Special Issue aims to redefine how we diagnose, treat, and conceptualize IBD and related disorders. Contributions from microbiology, gastroenterology, immunology, infectious diseases and translational research are strongly encouraged.

Guest Editors

Dr. Gaurav Agrawal

Division of Diabetes & Nutritional Sciences, Franklin-Wilkins Building, King's College London, London SE1 9NH, UK

Prof. Dr. Roger Pickup

Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, B078 Furness Building, Lancaster LA1 4YQ. UK

Deadline for manuscript submissions

28 February 2026



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/243838

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

